Press release
ABL Diagnostics is an international company listed on the regulated market of Euronext in Paris that specializes in innovative molecular biology tests and global solutions for its customers. Its parent company, Advanced Biological Laboratories SA (ABL SA), has entered into a share purchase and share loan agreement with Alumni Capital. Alumni Capital is an alternative investment fund specializing in opportunistic, event-driven strategies in small-cap equities worldwide, with an emphasis in the United States, the United Kingdom, the European Union, Canada, and Australia.
This agreement provides for successive sales of existing shares of ABL Diagnostics, at the initiative of ABL SA, combined with a share loan mechanism. It has a term of 24 months. It follows a first transaction announced in August 2025, under which ABL SA sold a block of ABL Diagnostics shares to Alumni Capital.
CMS Francis Lefebvre acted as legal advisor to Alumni Capital with a team comprised of Bertrand Sénéchal, partner, and Victor Delion, associate.
ABL SA was advised by ATOZ.
